Rheumatoid arthritis (RA) affects about 1% of the world's population and can lead to loss of joint function, reduced mobility, and permanent damage to cartilage and bone. Treatment options for RA primarily include disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, but the development of new drugs has complicated treatment decisions. Weighing treatment options for patients with RA largely depends on three major factors: efficacy, adverse reaction profile, and cost. A review of the literature supports methotrexate monotherapy as the current best-practice model for treating RA, compared with combination therapy of methotrexate and/or other DMARDs. Copyright © 2023 American Academy of Physician Associates.
Ihor Korol, Robin H Baumeister. Treating rheumatoid arthritis. JAAPA : official journal of the American Academy of Physician Assistants. 2023 Sep 01;36(9):1-5
PMID: 37668490
View Full Text